Dysphagia, Oropharyngeal, Oropharyngeal Cancer, Post Operative Pain, Transoral Robotic Surgery
Conditions
Keywords
oropharyngeal cancer, squamous cell carcinoma, postoperative pain, transoral robotic surgery
Brief summary
This study is for patients with oropharyngeal squamous cell carcinoma. We want to learn more about how we can optimize pain control in patients who undergo transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma. Our goal is to determine if a local anesthetic called EXPAREL® (Liposomal Bupivacaine) impacts postsurgical pain and swallow function in patients with oropharyngeal squamous cell carcinoma undergoing TORS. EXPAREL® is an FDA-approved anesthetic drug that provides long-lasting and precise pain relief when injected into the surgical wound. Our study team wants to determine if injecting EXPAREL® into the surgical wound will provide better pain relief and swallow function when compared to patients who do not undergo postoperative EXPAREL® injection. Both options for postoperative pain control are considered standard of care for patients undergoing TORS.
Interventions
DRUGLiposomal bupivacaine
We will inject liposomal bupivacaine into the surgical bed.
Sponsors
Geisinger Clinic
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients, greater than or equal to 18 years of age; Patients of all genders; Patients undergoing transoral robotic surgery; Patient who are able and willing to give consent
Exclusion criteria
* Patients with an allergy to Bupivacaine or other amide anesthetics; Patients with a carnitine deficiency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative Pain Control | 3 months | We will be measuring subjects' postoperative maximum visual analog pain scores on each postoperative day. Scale: 0-10, 0 represents no pain and 10 represents the worst pain |
| Postoperative Dysphagia with Endoscopic Swallow Study | 3 months | Patients will undergo a functional endoscopic swallow study with a speech language pathologist during their first postoperative visit. |
| Postoperative Dysphagia with Dysphagia Survey | 3 months | Patients will undergo an evaluation of their swallow function via the MD Anderson Dysphagia Inventory survey with a speech language pathologist during their first postoperative visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative Pain Medication Usage | 3 months | We will be measuring the doses of pain medication that patients requiring during their postoperative course. |
Countries
United States
Contacts
Primary ContactThorsen Haugen, MD
Outcome results
None listed